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Autocrine stimulation of growth of AR4-2J rat pancreatic tumour cells by
gastrin
M. Blackmoret & B.H. Hirst*
Gastrointestinal Drug Delivery Research Centre and Department ofPhysiological Sciences, University ofNewcastle upon Tyne,
Medical School, Newcastle upon Tyne NE2 4HH, UK.
Summary The control of cell proliferation by gastrin has been investigated in a rat pancreatic tumour cell
line, AR4-2J. Exogenous gastrin, 10-12 to 10-8 M, stimulated cell growth of thymidine-synchronised AR4-2J
cells cultured over 48 h in serum-free medium. Cell lysates of AR4-2J cells contained an average of 4.5 and
3.5 pg gastrin per 106 cells, when grown in serum-supplemented or serum-free media, respectively, as revealed
by radioimmunoassay. In serum-free medium, AR4-2J secrete 34ngl 10-6 cells of gastrin over 48h.
Addition of an anti-gastrin immunoglobulin preparation, but not control immunoglobulins, caused a maxi-
mum 52% reduction in cell growth. These data are consistent with an autocrine role for gastrin in the control
of AR4-2J cell growth. These results were supported by studies with gastrin/CCK receptor antagonists. Six
non-peptide gastrin/CCK receptor antagonists inhibited AR4-2J cell growth in a concentration-related man-
ner. The concentration required for 50% inhibition (IC50) of cell growth by the amino acid-derived antagonists
proglumide (3.5 x 10- M), benzotript (1.8 x 10-3 M), loxiglumide (1.1 x 10-4 M) and lorglumide (6.7 x
10-5 M) were of the same order and significantly correlated with their IC50 for inhibition of 1251-gastrin binding
to AR4-2J cells. Inhibition of cell growth by these antagonists was partially reversed by the addition of
exogenous gastrin. In contrast, the ICm for inhibition of cell growth with two benzodiazepine-derived
antagonists, the CCK-B receptor antagonist L-365,260 (4.6 x 10-5 M) and the CCK-A receptor antagonist
devazepide (1.7 x 10-' M) were two-three orders of magnitude greater than those required to inhibit gastrin
binding (10-8-10-7M). The growth inhibitory effects of L-365,260 and devazepide were not reversed by
exogenous gastrin suggesting these benzodiazepine-derived antagonists do not inhibit cell growth by inter-
action with gastrin receptors. The results are consistent with gastrin being an autocrine growth factor in
AR4-2J cells, and that stimulation of cell growth is due to stimulation of the gastrin, rather than CCK-B,
receptor sub-type. This study highlights that gastrin receptor antagonists warrant further investigation as
agents to control growth of tumours, such as those from the gastrointestinal tract, which express gastrin
receptors.
Gastrin, amongst its range of physiological actions, is a
trophic factor for the normal gastrointestinal mucosa
(Enochs & Johnson, 1977; Balas et al., 1985). There is in-
creasing evidence that gastrin is also a growth factor for
gastric and colonic cancers in vivo. Gastrin increases growth
of carcinogen-induced tumours of the rat colon and stomach
(McGregor et al., 1982; Yasui & Tahara, 1985). Long-term
hypergastrinaemia in man and rat is associated with entero-
chromaffin cell-like cell hyperplasia and gastric carcinoids
(Creutzfeldt, 1988). The trophic effects of gastrin on a trans-
plantable murine colonic adenocarcinoma in vivo and on
human gastric and colonic cancer xenografts in nude mice
are well recognised (Singh et al., 1986; Winsett et al., 1986;
Smith & Solomon, 1988; Watson et al., 1989). Similarly, the
structurally-related cholecystokinin (CCK) has been reported
to enhance pancreatic tumour formation in carcinogen-treat-
ed animals and growth of human pancreatic cancer xeno-
grafts in nude mice (Howatson & Carter, 1985; Smith et al.,
1990b). Gastrin receptors are found on a large proportion of
tumours from patients with colon cancers (Upp et al., 1989).
These studies linking tumour growth to gastrin have been
supported by the use of gastrin antagonists. Proglumide, a
non-specific gastrin/CCK receptor antagonist, inhibited the
growth stimulatory effects of gastrin on mouse colon cancer
in vivo and prolonged the survival of tumour-bearing mice
(Singh et al., 1987; Beauchamp et al., 1985). Direct trophic
effects of gastrin and CCK on gastrointestinal and pancreatic
tumour cells in vitro are widely reported (Sirinek et al., 1985;
Kusyk et al., 1986; Watson et al., 1988, 1989; Imdahl et al.,
1989; Guo et al., 1990; Smith et al., 1991). Inhibition of
gastrointestinal and pancreatic tumour cell growth by
gastrin/CCK receptor antagonists has also been shown by
several workers (Hoosein et al., 1988; Imdahl et al., 1989;
Guo et al., 1990; Smith et al., 1990a). These data provide
strong evidence for a role for gastrin in gastrointestinal and
pancreatic tumour cell growth, and suggest that gastrin
antagonists may provide a novel pharmacological approach
to anti-cancer therapy.
An autocrine role for gastrin in human colonic tumour cell
growth has been suggested, on the basis of studies with
anti-gastrin antibodies and gastrin/CCK antagonists (Hoo-
sein et al., 1988; 1990), but not confirmed in mouse colon
tumour cells (Guo et al., 1990). However, several groups
have suggested that a proportion of the inhibition of tumour
cell growth by proglumide, the most commonly used gastrin
antagonist for such studies, is unrelated to interaction with
gastrin receptors (Singh et al., 1987; Imdahl et al., 1989; Guo
et al., 1990). Moreover, a recent report has suggested that the
growth inhibitory effects of a potent CCK-A receptor anta-
gonist, devazepide (L-364,718), is also independent of its
interaction with gastrin or CCK receptors, while a potent
CCK-B receptor antagonist, L-365,260 was unable to inhibit
proliferation of several colonic cell lines in vitro (Thumwood
et al., 1991).
In the present study we have re-evaluated the role of
gastrin in the regulation of growth of a tumour cell line. The
AR4-2J rat pancreatic tumour cell line has been advocated
for studies of gastrin receptors. AR4-2J cells express both
CCK-A, coupled to stimulation of pancreatic enzyme secre-
tion, and gastrin/CCK-B receptors (Scemama et al., 1989;
Lambert et al., 1991). A trophic response to gastrin has been
shown in these cells which is coupled to the gastrin/CCK-B
receptor type (Scemama et al., 1989). Gastrin receptors in
AR4-2J cells have been characterised by binding studies (Sce-
mama et al., 1987, 1989; Lambert et al., 1991). The latter
point is important as earlier studies describing inhibition of
cell growth by gastrin/CCK receptor antagonists have not
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generally been correlated with receptor binding affinities. We
describe evidence for an autocrine role for gastrin in control
of AR4-2J proliferation and that proglumide and other
amino acid-derived gastrin/CCK antagonists act through
interaction with gastrin receptors.
Materials and methods
Cell culture
AR4-2J cells, a rat pancreatic tumour cell line derived from a
transplantable tumour of the acinar pancreas (Jessop & Hay,
1980), were obtained from the American Type Culture Col-
lection. Cells were maintained in subconfluent monolayer
culture at 37°C in an atmosphere of 5% C02/air in RPMI
1640 supplemented with 10% FCS, glutamine (2mM), peni-
cillin (100 U ml-) and streptomycin (100 tgml-1). For hor-
mone binding studies, AR4-2J cells were removed from their
flasks by washing with calcium and magnesium free phos-
phate buffered saline (PBS) and the exposing to 0.02% (w/v)
EDTA in PBS for 5 min. For routine passage, cells were
harvested with 0.025% (w/v) trypsin in versene.
HT-29 cells, a line derived from a human colonic adeno-
carcinoma, were obtained from the American Type Culture
Collection. Cells were maintained in subconfluent monolayer
culture at 37°C in an atmosphere of 5% C02/air in Dul-
becco's modified Eagle's media supplemented with 10% FCS,
glutamine (2mM), penicillin (10OUml-') and streptomycin
(100ptg ml-'). For all other procedures, HT-29 cells were
treated with similar protocols as described for AR4-2J cells.
Measurement ofcellproliferation
Cells were seeded into 96-well microtitre cell culture plates at
a concentration of 30,000 cells/well in 200 ftl RPMI medium
with 10% FCS. This density of cells was chosen such that
untreated cells were in the exponential phase of growth at the
end of the 48 h incubation period. After 24 h, the medium
was removed and replaced with 200 jil serum-free RPMI
containing 1 mM thymidine to accomplish synchronisation of
the cells in the G1/S phase of growth as described by Guo
and co-workers (1990). After 24 h, the cells were washed and
200tLI serum-free RPMI containing hG17-I were added to
the cells. Cell number was determined using the tetrazolium-
based colorimetric assay (MTT assay) originally described by
Mosmann (1983) and confirmed in some experiments by
direct cell counting using a haemocytometer (see below).
Following the 48 h incubation, 50 Al of MTT (3-(4,5,-di-
methylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, 1 mg
ml-') solution was added to each well and incubated at 37°C
for 4 h. The media were then removed from the wells and the
formazan crystals solubilised by adding 75 tLI of dimethylsul-
phoxide (DMSO). Plates were agitated on a plate shaker for
5 min, following which absorbance at 540 nm was immedi-
ately determined using a plate reader (Dynatech MR 5000).
Optical absorbance readings from test wells were corrected
against control wells containing cells plus serum-free medium
alone. When direct cell counts were required, media were
removed, cells were washed with 100 tlI PBS and harvested
by a 20 min incubation with 100 gI 0.025% (w/v) trypsin in
versene for resuspension in culture medium and counting in a
haemocytometer. In experiments using the anti-gastrin Ig
preparation half of the wells received dilutions of the control
Ig fraction at an identical protein concentration; both Ig
preparations had been previously dialysed against PBS. Incu-
bations with Ig preparations were carried out in serum-free
media for 4 days prior to measuring proliferation. Assess-
ment of cell growth in the presence of gastrin/CCK receptor
antagonists was made in a similar manner, however, incuba-
tions were carried out in the presence of 10% FCS over a 4
day period with a lower initial seeding density (10,000 or
3,000 cells/well for AR4-2J and HT-29 cells, respectively).
Control wells received media containing DMSO at the same
concentration present in the test wells (up to 0.5% v/v). The
effect of each reagent was investigated in between four and
ten wells on at least three separate occasions.
Ligandbinding studies
AR4-2J cells were harvested, washed three times with Eagle's
modified essential medium (EMEM) containing 0.1% (w/v)
bovine serum albumin (BSA) and 2 x 105 cells transferred to
1.5 ml polypropylene microcentrifuge tubes. Cells were incu-
bated with 2.5 x 10-10M of 251I-labelled ligand in the pre-
sence/absence of 2.5 x 101 M competing 'cold' ligand to
determine non-specific/specific binding or with various con-
centrations of gastrin/CCK receptor antagonists. Incubation
was carried out at 30°C for 60 min after which time the cells
were washed three times with EMEM plus 0.1% BSA and
cell-associated radioactivity was measured with a gamma
counter. The IC50 values for the various ligands was investi-
gated from duplicate evaluations at each concentration on at
least two separate occasions.
Measurement ofgastrin production by AR4-2J cells
AR4-2J culture supernatants and cells lysed in distilled water
were assayed for gastrin by radioimmunoassay, using a com-
mercial kit (CIS, London, UK). The detection limit of the
assay was 10 ng l-' and the anti-serum used recognises hG17-
1, hG17-11, hG34 and CCK with equal affinity. Standard
curves were constructed in distilled water for the assay of cell
lysates or in RPMI, with or without 10% FCS as appropri-
ate, for assay of culture supernatants.
Materials
Media were supplied by Gibco (Life Technologies, Paisley,
UK), foetal calf serum (FCS) by Globepharm Ltd (Surrey,
UK) and plastics by Nunc (Life Technologies). Human gas-
trin 17-1 (hG17-1) was from Bachem Ltd (Essex, UK). A
rabbit anti-human gastrin immunoglobulin (Ig) preparation
and a control rabbit Ig fraction prepared from sera of non-
immunised animals were obtained from DAKO Ltd (High
Wycombe, UK). The anti-gastrin Ig preparation reacts equal-
ly with hG17-1, hGl7-II and hG34 and cross reacts to more
than 50% with CCK-8. '25I-tyrosyl-iodinated human gastrin
('25I-hGl7-l, NEN-Dupont, Southampton, UK) with a specific
activity of 2,200Cimmolh' and a concentration of 50JLCi
ml-' was used in the gastrin receptor binding assays.
The benzodiazepine-derived CCK-A antagonist devazepide
[L-364,718; 3S (-)-N- (2,3-dihydro-l-methyl-2-oxo-5-phenyl-
1H-1, 4-benzodiazepine-3-yl) -1H-indole-2-carboxamide] and
gastrin/CCK-B antagonist L-365,260 [3R(+)-N-(2,3-dihydro-
1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl) -N'- (3-
methylphenyl)urea] were a gift of Merck Sharp & Dohme
Laboratories, West Point, PA, USA. The amino acid deriva-
tives, proglumide (D,L-4-benzamido- N,N-di-n-propylgluta-
ramic acid), proglumide-derived lorglumide [CR 1409; D,
L-4- (3,4-dichlorobenzoylamino)-5-(di-n-pentylamino)-5-oxo-
pentanoic acid] and loxiglumide [CR 1505; D,L-4-(3,4-di-
chlorobenzoylamino) -5- (N-3-methoxypropylpentylamino)-5-
oxo-pentanoic acid], and benzotript (N-p-chlorobenzoyl-L-
tryptophan), were a gift from Rotta Research Laboratories,
Milan, Italy. Gastrin/CCK antagonists were dissolved in
DMSO; controls including DMSO were included in each
experiment.
Data analyses
Estimates of half-maximal concentrations (IC50) of anta-
gonists required for inhibition of cell growth or gastrin bind-
ing were determined by non-linear regression analyses
(GraphPad). Scatchard analyses was performed by equili-
brium binding data analysis using LIGAND (Biosoft). Signi-
ficance of difference between means was investigated by
analysis ofvariance followed by Student's t-tests. Significance
was set at P<0.05.34 M. BLACKMORE & B.H. HIRST
Results
Effect ofgastrin on AR4-2Jproliferation
In preliminary experiments, addition of 5 x 1IOM to 5 x
10-6 M hGl7-I to asynchronous AR4-2J cells in serum-free
culture medium had no significant effect on proliferation
(data not shown). Subsequent experiments were, therefore,
carried out on thymidine-synchronised AR4-2J cells. AR4-2J
proliferation in the presence of hGl7-1 was assessed by the
MTT assay on five separate occasions. These experiments
were repeated by direct cell counting on one occasion with
similar results (data not shown). A bell-shaped concentra-
tion-response curve was obtained (Figure 1). Gastrin concen-
trations between 10-12 M and 1O0-M significantly increased
AR4-2J proliferation over a 48 h period, with the maximal
proliferative response observed between 5 x 10-12 M and
10"10M gastrin. There were no significant growth effects of
gastrin when used a concentrations < I0- 0 M or '_0- M.
Effect ofgastrin/CCK receptor antagonists on AR4-2J
proliferation
All of the antagonists tested inhibited unsynchronised AR4-
2J proliferation over a 4 day period in a concentration-
dependent manner. Figure 2 illustrates the results of three
separate experiments in which cell number was assessed by
the MTT assay; these data were confirmed on one occasion
by direct cell counts. Proglumide was the least potent inhib-
itor of AR4-2J cell growth, while devazepide was the most
effective. The rank order for inhibition of AR4-2J prolifera-
tion was devazepide>L-365,260 >lorglumide >loxiglumide
>benzotript> proglumide. The half maximal inhibitory con-
centration of each antagonist is given in Table I and ranged
from 3 mm (proglumide) to 17 fLM (devazepide).
Figure 3 illustrates the results of experiments in which
5 X 10-7 M gastrin was added to AR4-2J cells 2 h prior to
addition of the antagonists. Each antagonist was used at the
concentration previously determined to half maximally inhibit
AR4-2J growth (Table I). The inhibition of cell growth caused
by proglumide, benzotript, lorglumide and loxiglumide was
partially reversed by prior addition of gastrin. In contrast,
inhibition of AR4-2J cell growth by L-365,260 and devazepide
was not significantly effected by prior addition of gastrin.
We examined the ability of the gastrin receptor antagonists
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Figure 1 Effect of various concentrations of gastrin on the pro-
liferation of synchronised AR4-2J cells. Experiments were carried
out as detailed in the Methods with proliferation assessed by the
MTT assay. Each point represents the mean of 12 determinations
from two separate experiments; error bars represent the standard
error of the mean (s.e.m.). Similar results were obtained in a
further three experiments with the MTT assay and a single
experiment with direct cell counting over a limited range of
gastrin concentrations. Proliferation is normalised to control
wells which received fresh serum-free medium containing no exo-
genous gastrin. *P<0.05 compared with control.
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Figure 2 Effect of a 4 day incubation of AR4-2J cells with
varying concentrations of the gastrin/CCK receptor antagonists
proglumide, benzotript, loxiglumide, lorglumide, L-365,260 and
devazepide. Experiments were carried out as detailed in the
Methods with proliferation assessed by the MTT assay. Each
point represents the mean of at least 30 determinations from
three separate experiments; error bars represent s.e.m. Prolifera-
tion is normalised to control wells which received fresh medium
containing the same amount of DMSO used in test wells. 0,
proglumide; *, benzotript; 0, loxiglumide; A, lorglumide; V,
L-365,260; *, devazepide.
Table I Estimates of concentrations of gastrin/CCK antagonists
required to inhibit growth and '251-hGl7-l binding to AR4-2J cells
AR4-2J HT-29
IC50(M) IC50 (M) IC50 (M)
Antagonist Growth inhibition Receptor binding Growth inhibition
Proglumide 3.5 x 10-3 1.3 x 10-3 1.4 x 10-2
Benzotript 1.8 x 10-3 2.6 x 10-4 3.4 x 1O-3
Loxiglumide 1.1 X 10-4 3.0 x 10-5 4.7 x 10-4
Lorglumide 6.7 x 10-5 1.5 x 1-0 1.5 x 10-4
L-365,260 4.6 x 10-5 1.0 X l0-8 2.2 x 10-5
Devazepide 1.7 x i0- 1.2 x 10- > l0-4
IC50 values for growth inhibition were calculated from three experi-
ments using the MTT assay (Figure 2) and oneexperiment using direct
cell counts. IC50 values for growth inhibition ofHT-29 were calculated
for three experiments using the MTT assay.
to inhibit the growth of HT-29 cells. In this cell line we were
unable to detect specific '25I-hGl7-1 binding or endogenous
gastrin, and neither exogenous gastrin nor an anti-gastrin Ig
preparation effected proliferation. All six gastrin/CCK anta-
gonists inhibited HT-29 cell proliferation with the rank order
of potency similar, except for devazepide, to that observed for
AR4-2J cells (Table I). The ICo values for inhibition of HT-29
proliferation by the amino acid derivatives were 2-4 fold
greater than in AR4-2J cells. Devazepide did not achieve 50%
inhibition of HT-29 proliferation at concentrations up to and
including 10-4 M.
Effect ofan anti-gastrin Ig preparation on AR4-2Jproliferation
When unsynchronised AR4-2J cells were cultured in serum-
free medium in the presence of a dialysed anti-gastrin Ig
preparation a significant concentration-related reduction in
proliferation occurred compared to wells which received
serum-free medium alone (Figure 4). Pre-incubation of the
anti-gastrin Ig with 50 1gml-' hG17-1 for 24h partially
reversed the inhibition of proliferation observed on culture
with a 1/40 dilution of this reagent (from 45.5% inhibition to
23.0% inhibition with the anti-gastrin Ig alone or with gastrin
pre-incubation, respectively). No growth effects of the same
dilutions of the control Ig preparation were apparent.
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Figure 3 Effect of exogenous gastrin on the inhibition of prolif-
eration caused by the gastrin/CCK receptor antagonists. Gastrin,
5 x 10-7 M, was added 2 h prior to the addition of proglumide,
benzotript, loxiglumide, lorglumide, L-365,260 or devazepide.
Proliferation was assessed by the MTT assay. A total of 18
determinations in three separate experiments were carried out for
each antagonist; error bars represent s.e.m. The antagonist con-
centrations used were those quoted in Table I as being the
concentrations required to half maximally inhibit AR4-2J cell
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wells which received fresh medium containing no added gastrin
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Figure 5 Gastrin-like immunoreactivity in AR4-2J cells grown in
serum-free medium. Standard curve for hG17-1 in the radio-
immunoassay is illustrated (bottom scale, M) together with a
dilution curve for 4 x 107 AR4-2J cell lysates (top scale, 0),
illustrating parallelism with the standard curve, and 48 h condi-
tioned serum-free medium (0). Each point represents the mean
of duplicate determinations.
different to the value obtained from cells grown in serum-
supplemented medium. Gastrin-like immunoreactivity was also
observed in the media collected from cells cultured under
serum-free conditions (Figure 5). Over a 48 h period, AR4-2J
cells secreted 34 ngV' 106 cells.
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Figure 4 Effect of dialysed anti-gastrin and control Ig prepara-
tions on the growth of AR4-2J cells in serum-free medium. At
least 12 determinations in two separate experiments were carried
out for each experimental condition; error bars represent s.e.m.
Proliferation was assessed by the MTT assay and is normalised to
control wells which received serum-free medium alone. *P<0.05
compared with control. EOII, anti-gastrin Ig preparation; 1M,
control Ig preparation.
Gastrin receptor analyses
'25I-hGl7-1 binding to AR4-2J cells was displaced by un-
labelled hG17-1 with an IC50 of 1.9 x 10-9M. From Scat-
chard analyses of four separate experiments, the apparent
dissociation constant for gastrin was 4.6 ± 0.8 x 10-9 M, with
a maximum binding capacity of 89.3 ± 58.3 fmol 10-6 cells.
Figure 6 illustrates the displacement of 25I-hGl7-1 binding
to AR4-2J cells by proglumide, benzotript, loxiglumide, lor-
glumide, L-365,260 and devazepide. The IC50 values for each
antagonists are given in Table I. The two benzodiazepine
derivatives (devazepide and L-365,260) were the most potent
in displacing i25I-hG17-l binding, with the CCK-B antagonist
L-365,260 the most potent. Lorglumide and loxiglumide
showed similar potencies in displacing gastrin binding. Pro-
glumide and benzotript were the least potent antagonists
tested with IC5s values of 1.3 mM and 0.26 mM, respectively.
Consideration of Table I reveals that the concentrations of
proglumide, benzotript, loxiglumide and lorglumide required
to half maximally inhibit AR4-2J cell growth were within an
order of magnitude of the half-maximal concentrations
required to displace i25I-hG17-1 binding and there was a
good correlation between these two variables (Figure 7). In
contrast, much higher concentrations of L-365,260 and deva-
zepide were required for inhibition of AR4-2J cell growth
than those required to displace gastrin binding (Figure 7).
Discussion
Endogenous gastrin in AR4-2J cells
Lysates of AR4-2J cells cultured in serum-supplemented
medium contained gastrin-like immunoreactivity which diluted
in parallel with standard gastrin. From a total of 24 deter-
minations on three separate occasions, a mean value of 4.5 pg
equivalent to hG17-1 per 106 AR4-2J cells was estimated.
Immunoreactive gastrin in the medium collected from up to
4 x 107 AR4-2J cells cultured over a 48 h period in RPMI
containing 10% FCS was at the limit ofdetection ofthe assay.
AR4-2J cells cultured for 48 h in serum-free RPMI also con-
tained gastrin-like immunoreactivity which diluted in parallel
with standard gastrin (Figure 5), giving a mean value of 3.5 pg
equivalent to hG17-1 per 106 cells, which was not significantly
Proliferation of AR4-2J rat pancreatic tumour cells in vitro
was stimulated by exogenous gastrin, inhibited by anti-
gastrin antibodies and by gastrin receptor antagonists. In
addition, AR4-2J cells contain and secrete immunoreactive
gastrin. These results indicate an autocrine role for gastrin-
like peptides in the regulation of growth in this cell line. The
lack of correlation of inhibition of AR4-2J proliferation and
displacement of gastrin binding observed with devazepide
and L-365,260 suggest that the growth inhibitory actions of
these two compounds is unlikely to be mediated via gastrin/
CCK receptors.
A direct and significant trophic effect of exogenous gastrin
was found on AR4-2J cells growth arrested with 1.0 mM
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Figure 6 Displacement of 251I-hGl7-l binding to AR4-2J cells
by varying concentrations of proglumide, benzotript, loxiglumide,
lorglumide, devazepide and L-365,260. Data were obtained from
duplicate determinations in two to three separate experiments.
Binding is normalised to the maximum specific binding of '25I-
hG17-1. 0, proglumide; *, benzotript; 0, loxiglumide; A, lor-
glumide; V, L-365,260; *, devazepide.
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Figure 7 Correlation between inhibition of '25I-hGl7-l binding
and inhibition of AR4-2J proliferation for the gastrin/CCK
receptor antagonnists. The correlation line through the data for
proglumide, benzotript, loxiglumide and lorglumide (correlation
coefficient = 0.96) is illustrated. 0, proglumide; *, benzotript;
0, loxiglumide; A, lorglumide; V, L-365,260; 0, devazepide.
thymidine; no such growth effects were observed with asyn-
chronous cells. Specific culture conditions involving synchro-
nisation of cells with thymidine and growth in serum-free
medium have been reported previously to be important in
revealing trophic effects of gastrin on gastric and colon
cancer cells in vitro (Kusyk et al., 1986; Watson et al., 1988;
Guo et al., 1990). In previous studies, ornithine decarbox-
ylase activity, or 3H-thymidine or 75Se-selenomethionine
incorporation were used as indices of responsiveness of AR4-
2J cells to gastrin (Scemama et al., 1989; Seva et al., 1990;
Watson et al., 1991a). Interpretation of data obtained by the
latter approach is frustrated by the fact that gastrin increases
secretion, and presumably synthesis, of proteins such as the
enzyme amylase from AR4-2J cells (Lambert et al., 1991).
We assessed cell numbers using the MTT assay which relies
on the ability of viable cells to reduce tetrazolium to for-
mazan. It is recognised that this assay might be influenced by
a variety of factors independent of cell numbers, including
chemical interference with the tetrazolium or cellular enzy-
mes, or cellular metabolic conditions (Scudiero et al., 1988).
However, the MTT assay has been shown to provide a
reproducible index of cell proliferation in comparison with
assays ofcell protein in over 30 human and other tumour cell
lines (Alley et al., 1988; Rubinstein et al., 1990), and in our
study we confirmed the MTT results with direct cell counts.
Gastrin at 1IO-2 M increased the proliferation of AR4-2J cells
and at this low concentration would not be expected to
interact with CCK-A receptors, as these require gastrin to be
present in the micromolar range. This conclusion is sup-
ported by the rank order of potency of the antagonists for
displacement of '251-hGl7-l binding which is consistent with
interaction at gastrin/CCK-B receptors. Previous studies have
provided further evidence for growth stimulation coupled to
gastrin/CCK-B, and not CCK-A receptors in AR4-2J cells
(Scemama et al., 1989). The response in pancreatic AR4-2J
tumour cells contrasts with that in the normal mouse pan-
creatic acinar cells in which the growth response to gastrin is
reported to be mediated via the CCK-A receptor (Logsdon,
1987). Human pancreatic cancer cell growth is stimulated by
CCK (Smith et al., 1990b; 1991); the receptors mediating this
response require evaluating. The sequence of events linking
occupation of gastrin/CCK-B receptors to enhanced cell
division has yet to be elucidated, but early events may in-
clude the activation of Na+/H+ exchange (Bastie et al., 1988)
and ornithine decarboxylase (Scemama et al., 1989).
The inhibition of AR4-2J proliferation by the anti-gastrin
Ig preparation is evidence for an autocrine role for gastrin-
like peptides in the growth regulation of these cells. Similarly,
Hoosein and co-workers (1988, 1990) demonstrated that a
gastrin antiserum, as well as gastrin/CCK receptor antagon-
ists, inhibited proliferation of six human colonic cancer cell
lines and suggested that gastrin-like peptides may function as
autocrine growth factors in these cells. In the present study,
the reduction in cell growth in the presence of the anti-
gastrin reagent was very dramatic with a maximal mean
reduction in proliferation of 52%. This would imply that
gastrin-like peptides are very important autocrine growth
factors for these cells and would explain the relatively small
growth response to exogenous gastrin. An autocrine regula-
tory role for gastrin is supported by the presence of gastrin-
like immunoreactivity in AR4-2J cells. The amount of
gastrin-like immunoreactivity secreted by the cells was
towards the detection limit of the assay, but within the range
of concentrations of exogenous gastrin required to stimulate
proliferation. Gastrin-like immunoreactivity has recently been
reported in several human gastric and colonic tumour cell
lines and this is secreted into the medium (Hoosein et al.,
1990; Watson et al., 1991b). That this immunoreactivity
reflects endogenous gastrin-like peptides has been confirmed
by detection and sequencing of gastrin mRNA in these cells
(Hoosein et al., 1990; Baldwin et al., 1990). The nature of the
gastrin-like immunoreactivity in AR4-2J cells has yet to be
elucidated.
All of the gastrin/CCK receptor antagonists tested inhibit-
ed AR4-2J proliferation over a 4 day period. It has been
suggested by some investigators that proglumide-inhibition of
cellular proliferation may be a result of non-specific effects
rather than its ability to interact with gastrin receptors
(Imdahl et al., 1989; Singh et al., 1987; Guo et al., 1990). The
concentrations of proglumide, benzotript, lorglumide and
loxiglumide required for half maximal inhibition of AR4-2J
cell growth were directly related to the concentrations
required to displace 50% of specific 1251-hGl7-1 binding to
gastrin/CCK-B receptors, consistent with growth inhibitory
actions mediated through gastrin/CCK-B receptor antagon-
ism. However, these same antagonists also reduced prolifera-
tion of a cell line, HT-29, in which we were unable to
demonstrate specific '25I-hGl7-1 binding. This might be taken
as evidence that the growth inhibitory effects of these anta-
gonists are non-specific in nature. Alternatively, the inhibi-
tion of HT-29 proliferation by these compounds may indicate
that gastrin receptors are expressed on HT-29 cells, but at
levels too low to allow detection by i25I-hG17-1 binding. In
addition, the inhibition of AR4-2J proliferation caused by
the amino acid derivatives was partially reversed by gastrin,GASTRIN AND PANCREATIC CELL GROWTH 37
again consistent with involvement, at least in part, of gastrin
receptors in the mechanism of action of these antagonists. In
contrast, the two benzodiazepine derivatives (L-365,260 and
devazepide) did not appear to inhibit AR4-2J cell growth by
interaction with gastrin/CCK-B receptors. Much greater con-
centrations (several orders ofmagnitude) of these compounds
were required to inhibit AR4-2J cell proliferation as com-
pared with their ability to compete with 1251I-hGl7 binding.
Inhibition of AR4-2J cell growth by these latter two agents
was not reversible with exogenous gastrin. These results with
L-365,260 and devazepide are similar to those recently
reported by Thumwood et al. (1991) who found that devaze-
pide in high concentrations inhibited the growth of a variety
of cell lines but that this inhibition could not be reversed by
addition ofgastrin or CCK. These workers failed to observed
inhibition of cell growth with the specific gastrin CCK-B
receptor antagonist L-365,260, probably a reflection of the
concentrations investigated, which were lower than in the
present study. Devazepide and L-365,260 have gained in
popularity as tools to define gastrin/CCK receptor sub-types
since their introduction as specific CCK-A and CCK-B recep-
tor antagonists. The results from the present study would
urge caution in their unqualified use for such studies.
A hypothesis to account for the results obtained in the
present study with L-365,260 and devazepide would be the
existence of two gastrin/CCK-B receptor sub-types on AR4-
2J cells; one major sub-type which recognises all six of the
antagonists with varying affinity but which is not linked to
cell growth processes and a second minor receptor sub-type
with low affinity for L-365,260 and devazepide, but similar
affinity to the first receptor sub-type for the other antagonists
and which is responsible for the growth effects of gastrin on
AR4-2J cells. In this hypothesis, it would be postulated that
L-365,260 and devazepide decrease AR4-2J proliferation by a
receptor-independent mechanism, consistent with the failure
of exogenous gastrin to reverse the inhibition. At this time,
the existence of such receptor sub-types on AR4-2J cells is
speculation. The existence of distinct gastrin and CCK-B, as
well as CCK-A, receptors has been argued by others on the
basis of agonist studies (Jensen et al., 1989), although
previous studies with the benzodiazepine-derived antagonists
have suggested that gastrin and CCK-B receptors are equiva-
lent (Freidinger et al., 1989). Functional studies using L-
365,260 report it to have a lower affinity than predicted from
binding studies in gastric mucosa; estimates of binding
affinity may reflect interaction with CCK-B receptors, while
the biological response may be a result of interaction with
gastrin receptors (Patel & Spraggs, 1992). Three types of
gastrin/CCK receptors have been discerned on guinea-pig
smooth muscle cells from protection studies (Grider &
Makhlouf, 1990). To extrapolate to the present results, on
the basis of the studies with antagonists, gastrin receptor
binding displacement may be an indication of CCK-B recep-
tor affinity while inhibition of cell proliferation may be a
consequence of gastrin receptor antagonism. However, the
rank order for displacement of gastrin binding by agonists in
AR4-2J cells suggested that gastrin binding is mainly a
reflection ofgastrin, rather than CCK-B, receptors (Scemama
et al., 1989). Obviously, further investigation is required to
clarify which receptor sub-types reflect which functions.
In conclusion, we have shown a direct trophic effect of
exogenous gastrin on AR4-2J rat pancreatic tumour cells.
Evidence was also found for gastrin acting as an autocrine
growth regulatory factor in these cells; significant concentra-
tions of gastrin-like immunoreactivity were determined in
lysates of AR4-2J cells and their proliferation was inhibited
by gastrin/CCK receptor antagonists and by an anti-gastrin
Ig preparation. From this study it would appear that gastrin
receptor antagonists, or compounds which interfere with gas-
trin release by tumour cells, warrant further investigation as
possible anti-tumour agents for cancers which express gastrin
receptors. In this respect gastrin, rather than CCK-B, recep-
tor antagonists would appear to be more promising.
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